NDA 020500 · Glaxosmithkline LLC
Mepron
Atovaquone · Oral · Antimalarial; Antiprotozoal
Priority reviewLast checked: Nov 20, 2026Latest source record: Mar 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1995
Feb 8, 1995
Approved uses
2
Original approval plus efficacy supplements
Registered trials
57
5 Phase 3, 2 recruiting
FAERS reports
8,218
7,018 serious, 1,382 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 20, 2026.
MEPRON oral suspension is a quinone antimicrobial drug indicated for: • Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1 ) • Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. ( 1.2 ) Limitations of Use ( 1.3 ) : • Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with MEPRON has not been studied. • The efficacy of MEPRON in subjects who are failing therapy with TMP-SMX has also not been studied. 1.1 Prevention of Pneumocystis jirovecii Pneumonia MEPRON oral suspension is indicated for the prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents (aged 13 years and older) who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). 1.2 Treatment of Mild-to-Moderate Pneumocystis jirovecii Pneumonia MEPRON oral suspension is indicated for the acute oral treatment of mild-to-moderate PCP in adults and adolescents (aged 13 years and older) who cannot tolerate TMP-SMX. 1.3 Limitations of Use Clinical experience with MEPRON for the treatment of PCP has been limited to subjects with mild-to-moderate PCP (alveolar-arterial oxygen diffusion gradient [(A-a)DO 2 ] ≤45 mm Hg). Treatment of more severe episodes of PCP with MEPRON has not been studied. The efficacy of MEPRON in subjects who are failing therapy with TMP-SMX has also not been studied.
Mechanism: Atovaquone is a quinone antimicrobial drug [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 5, 1999 Supplement 5 · Efficacy ReviewLabelLetter
- Feb 8, 1995 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- MEPRON · ATOVAQUONE 750MG/5ML · SUSPENSION, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Atovaquone" as an intervention, any sponsor and status, largest first.
- A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or SulfonamidesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000802 · 700 participants
Drug: Atovaquone; Dapsone · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Birmingham, Alabama; Los Angeles, California; Palo Alto, California · 44 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000811 · 690 participants
Drug: Azithromycin; Atovaquone and 1 more · For: Bacterial Infections; Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Birmingham, Alabama; Mobile, Alabama; La Jolla, California · 75 sites in all
- Chloroquine Alone or in Combination for Malaria in Children in MalawiPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00379821 · 640 participants · Start Feb 2007 · Primary completion Aug 2009
Drug: Atovaquone-proguanil; Artesunate and 2 more · For: Plasmodium Falciparum Infection
Sites: Blantyre, Malawi
- A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMXPivotal-lookingCompleted
Glaxo WellcomeGSK (GSK)
NCT00002340 · 615 participants
Drug: Atovaquone; Pentamidine isethionate · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Maitland, Florida; Tampa, Florida; New York, New York · 5 sites in all
- A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07917754 · 470 participants (planned) · Start Dec 13, 2026 · Primary completion Mar 13, 2037
Drug: MK-1045; Zilovertamab vedotin and 8 more · For: Lymphoma, Large B-Cell, Diffuse; Diffuse Large B-Cell Lymphoma
- Positioning Second-line Therapies for Pneumocystis Jirovecii Pneumonia (PCP Alternatives)Pivotal-lookingNot yet recruiting
McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
NCT07357103 · 416 participants (planned) · Start Mar 2026 · Primary completion Mar 2029
Drug: Clindamycin + primaquine; Pentamidine and 1 more · For: Pneumocystis; Pneumocystis Infection; Pneumocystis Carinii Infection and 5 more
- Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated MalariaPivotal-lookingCompleted
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT01150344 · 317 participants · Start Jul 2010 · Primary completion Apr 2014
Drug: Malarone (atovaquone + proguanil combination); RIAMET (artemether + LUMEFANTRIN combination) · For: Malaria
Sites: Bobigny, France
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000655 · 300 participants · Primary completion Jan 1992
Drug: Atovaquone; Sulfamethoxazole-Trimethoprim · For: Pneumonia, Pneumocystis Carinii; HIV Infections
Sites: Birmingham, Alabama; Harbor City, California; Los Angeles, California · 38 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use833
- pyrexia453
- diarrhoea435
- drug ineffective426
- nausea406
- pneumonia393
- death323
- fatigue313
- dyspnoea298
- acute kidney injury292
- neutropenia279
- condition aggravated278
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 42 |
| 2005 | 52 |
| 2006 | 52 |
| 2007 | 60 |
| 2008 | 82 |
| 2009 | 105 |
| 2010 | 90 |
| 2011 | 89 |
| 2012 | 126 |
| 2013 | 134 |
| 2014 | 170 |
| 2015 | 209 |
| 2016 | 240 |
| 2017 | 272 |
| 2018 | 373 |
| 2019 | 403 |
| 2020 | 570 |
| 2021 | 668 |
| 2022 | 836 |
| 2023 | 956 |
| 2024 | 993 |
| 2025 | 986 |
| 2026 | 710 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mepron (Atovaquone)
2024 spending
$251K
Beneficiaries
28
144 claims
Per beneficiary
$8,977
$6.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $423,828 |
| 2021 | $435,587 |
| 2022 | $316,549 |
| 2023 | $322,206 |
| 2024 | $251,362 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Prosty C, Katergi K, Sorin M, et al. · Clin Microbiol Infect 2024 · Systematic Review, Comparative Study
- Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.
Hatzl S, Posch F, Scholz L, et al. · Clin Microbiol Infect 2025 · Systematic Review, Comparative Study
- Malaria: prevention in travellers.
Croft AM · BMJ Clin Evid 2007 · Systematic Review
- Malaria: prevention in travellers.
Croft AM · BMJ Clin Evid 2010 · Systematic Review
- HIV: treating Pneumocystis pneumonia (PCP).
Bellamy RJ · BMJ Clin Evid 2008 · Systematic Review
- Drugs for preventing malaria in travellers.
Jacquerioz FA, Croft AM · Cochrane Database Syst Rev 2009 · Meta-Analysis, Systematic Review
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.